Core Insights - The company reported a total revenue of 1.23 billion and a net profit of 142 million for the year 2024, showing a year-on-year growth of 22.18% [1] - In Q1 2025, the company achieved a revenue of 232 million, with a year-on-year increase of 8.90%, and a net profit of 25.67 million, reflecting a growth of 15.92% [1] - The company demonstrated strong resilience in a challenging industry environment [1] Product Development - The company is the first in China to successfully develop a high-cure-rate pan-genotype all-oral series of drugs for hepatitis C, with its core product, the sodium colopavine capsule series, continuing to release strong clinical value [1] - The sodium colopavine capsule successfully renewed its inclusion in the medical insurance catalog in 2024, solidifying its market position and laying a strong foundation for future business expansion [1] Market Strategy - The company has implemented innovative market strategies to address patient access issues in grassroots markets, including deep academic collaborations with liver disease experts and further penetration into county-level markets [1] - The company’s mature products, particularly the interferon series, continue to maintain market leadership, with significant evidence supporting their clinical value [2] - The company’s products, Jinshuxi and Kaiyin Yisheng, have been included in the inter-provincial collection alliance for interferon in 29 provinces, marking a new breakthrough in the centralized procurement field [2] Future Outlook - The company plans to focus on expanding the hepatitis C innovative drug market while deepening its advantageous strategies and promoting county-level marketing [2] - The company aims to enhance the sales scale of mature products through CSO cooperation and brand expansion, continuously optimizing operational performance to create value for shareholders [2]

4月28日，凯因科技(688687)披露2024年年度报告和2025年一季报。公司2024年度实现营业收入12.30亿 元，归母净利润1.42亿元，同比增长22.18%；2025年一季度实现营收2.32亿元，同比增长8.90%，归母 净利润2566.85万元，同比增长15.92%。公司维持较高研发投入强度，2024年研发投入1.57亿元，占营 业收入比例为12.79%，同比增加0.57个百分点。核心项目取得突破性进展 报告期内，公司多个研发项目取得突破性进展：KW-001(培集成干扰素α-2注射液乙肝适应症)完成Ⅲ期 临床试验并提交药品注册上市许可申请；KW-045(人干扰素α2b喷雾剂)针对儿童疱疹性咽峡炎适应症 Ⅱa期临床试验全部受试者完成治疗及随访；KW-051(培集成干扰素α-2注射液带状疱疹适应症)Ⅱ期临床 试验全部受试者完成治疗及随访；KW-053人干扰素α2b阴道泡腾片辅助治疗尖锐湿疣适应症取得药物临 床试验批准通知书，Ⅱ期试验推进中；GL-004(马来酸阿伐曲泊帕片)取得药品注册证书。 公司于2024年共申请发明专利9项，获得发明专利授权7项；至报告期末，累计申请发明专利175项，累 计获得发 ...